Spectral AI (MDAI) Q4 2024 earnings summary

Executive summary

• Achieved significant milestones in 2024, including positive top-line results from a major burn validation study demonstrating DeepView's superior diagnostic performance over clinicians in sensitivity, Dice score, and specificity.

• Achieved $29.6M in FY 2024 R&D revenue, up 63.5% year-over-year, driven by BARDA PBS contract.

• Expanded global presence with successful DeepView deployments in Australia and the U.K., gathering real-world clinical feedback to support FDA submission and commercialization.

• Formed Spectral IP, an intellectual property subsidiary, and announced plans to spin it off as a separate public company by Q2 2025, focusing on IP monetization in healthcare and technology sectors.

• Secured multi-year, non-dilutive BARDA PBS contract valued up to $150M, supporting development and procurement.

Financial highlights

• Q4 2024 R&D revenue was $7.6 million, up from $5.3 million in Q4 2023, driven by increased BARDA contract work.

• Full year 2024 R&D revenue reached $29.6 million, a 63.5% increase year-over-year, marking a company record.

• Gross margin for 2024 improved to 44.9% from 43.6% in 2023, reflecting higher reimbursement rates under the current BARDA contract.

• Q4 2024 net loss: $(7.7)M, $(0.41)/share; FY 2024 net loss: $(15.3)M, $(0.85)/share.

• Cash and cash equivalents stood at $5.2 million at year-end, rising to over $14 million after recent long-term debt and equity financing.

Outlook and guidance

• Forecasting $21.5 million in revenue for fiscal year 2025, not including potential commercial sales from the U.K. or Australia.

• 2025 expected to be a transitional year with lower revenue as focus shifts to FDA submission and preparation for commercialization, with ramp-up anticipated in 2026.

• Plans to submit FDA application for DeepView System for burns by end of Q2 2025; FDA decision anticipated in early 2026.

• Expects first commercial product revenue in H2 2025 and commercial revenue across four DeepView platforms within three years.

• DeepView Snapshot M targeted for military deployment in 2027, with ongoing development milestones and further government funding expected.